Search

Author/Creator Pieczonka, Christopher

1. Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC). Issue 2 (December 2015)

Authors:
Drake, Charles; Quinn, David; Dreicer, Robert; Antonarakis, Emmanuel; Shore, Neal; Corman, John; Concepcion, Raoul; Pieczonka, Christopher; Campogan, Dwayne; Fan, Li-Qun; Chang, Nancy; Sheikh, Nadeem; Petrylak, Daniel
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3:Issue 2(2015)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC). (4th November 2015)

Authors:
Drake, Charles G; Quinn, David; Dreicer, Robert; Antonarakis, Emmanuel; Shore, Neal; Corman, John; Concepcion, Raoul; Pieczonka, Christopher; Campogan, Dwayne; Fan, Li-Qun; Chang, Nancy; Sheikh, Nadeem; Petrylak, Daniel
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Impact of darolutamide on local symptoms: pre‐planned and post hoc analyses of the ARAMIS trial. (29th September 2022)

Authors:
Shore, Neal D.; Stenzl, Arnulf; Pieczonka, Christopher; Klaassen, Zachary; Aronson, William J.; Karsh, Lawrence; Ryan, Charles J.; Ortiz, Jorge; Srinivasan, Shankar; Mohamed, Ateesha F.; Verholen, Frank
Journal:
BJU international
Issue:
Volume 131:Number 4(2023)
Page Start:
452
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. MP27-15 SABIZABULIN HAS BOTH CYTOTOXIC AND CYTOSTATIC ACTIVITY IN PHASE 1B/2 CLINICAL OF MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER WHO PROGRESSED ON ANDROGEN RECEPTOR TARGETING AGENTS. (May 2022)

Authors:
Markowski, Mark; Eisenberger, Mario; Pieczonka, Christopher; Getzenberg, Robert; Rodriguez, Domingo; Barnette, K. Gary; Steiner, MItchell; Saltzstein, Daniel; Antonarakis, Emmanuel; Tutrone, Ronald
Journal:
Journal of urology
Issue:
Volume 207(2022)Supplement 5
Page Start:
e456
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Optimizing the management of castration‐resistant prostate cancer patients: A practical guide for clinicians. Issue 14 (11th August 2020)

Authors:
Shore, Neal D.; Drake, Charles G.; Lin, Daniel W.; Ryan, Charles J.; Stratton, Kelly L.; Dunshee, Curtis; Karsh, Lawrence I.; Kaul, Sanjeev; Kernen, Ken; Pieczonka, Christopher; Sieber, Paul; Stewart, Christopher; Williams, Michael; Concepcion, Raoul S.
Journal:
Prostate
Issue:
Volume 80:Issue 14(2020)
Page Start:
1159
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗